The SAPA-China 2025 Pharmaceutical Industry Conference will be grandly held from October 31 to November 1, 2025, at the Shishan International Conference Center in Suzhou.
Under the theme “Building an Innovative Ecosystem, Opening a New Era in Pharmaceuticals,” the conference will feature one main forum and 45 parallel sub-forums, bringing together nearly 400 top leaders and renowned experts from across the pharmaceutical industry.
Discussions will cover cutting-edge fields such as innovative large and small molecule drugs, cell and gene therapy, AI-driven drug discovery, nucleic acid therapeutics, advanced and novel formulations, GLP-1 and metabolic disorders, synthetic biology, clinical research, ophthalmology, medical aesthetics, international collaboration, and investment & financing. Through keynote presentations, panel discussions, corporate exhibitions, and one-on-one business meetings, the event aims to comprehensively foster communication and collaboration, with more than 8,000 attendees expected on-site.
DIMA Biotech will showcase its latest research achievements at the event (Booth No. A32). We sincerely invite industry experts, scholars, and partners to visit our booth for in-depth exchanges and discussions, and to explore future opportunities for collaboration in advancing biopharmaceutical innovation.
About DIMA
DlMA BIOTECH is an innovative biotechnology company focusing on antibody discovery for pre-clinical research. DIMA possesses a number of innovative and proprietary technology platforms, such as Nanodisc membrane protein purification technology, Single B recombinant mAb cloning technology, etc. All these technology platforms are perfectly integrated in our therapeutic lead antibody discovery program.
Our customer centric business model with zero upfront payment and off-the-shelf lead antibody molecules offerings can further expedite Biopharma’s pre-clinical research needs.
